These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27567079)

  • 1. Discovery of a 7-arylaminobenzimidazole series as novel CRF1 receptor antagonists.
    Mochizuki M; Kori M; Kono M; Yano T; Sako Y; Tanaka M; Kanzaki N; Gyorkos AC; Corrette CP; Aso K
    Bioorg Med Chem; 2016 Oct; 24(19):4675-4691. PubMed ID: 27567079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF
    Mochizuki M; Kojima T; Kobayashi K; Kotani E; Ishichi Y; Kanzaki N; Nakagawa H; Okuda T; Kosugi Y; Yano T; Sako Y; Tanaka M; Aso K
    Bioorg Med Chem; 2017 Mar; 25(5):1556-1570. PubMed ID: 28174066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
    Mochizuki M; Kori M; Kobayashi K; Yano T; Sako Y; Tanaka M; Kanzaki N; Gyorkos AC; Corrette CP; Cho SY; Pratt SA; Aso K
    J Med Chem; 2016 Mar; 59(6):2551-66. PubMed ID: 26901666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.
    Kojima T; Mochizuki M; Takai T; Hoashi Y; Morimoto S; Seto M; Nakamura M; Kobayashi K; Sako Y; Tanaka M; Kanzaki N; Kosugi Y; Yano T; Aso K
    Bioorg Med Chem; 2018 May; 26(9):2229-2250. PubMed ID: 29459145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
    Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.
    Ahuja VT; Hartz RA; Molski TF; Mattson GK; Lentz KA; Grace JE; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2016 May; 26(9):2184-7. PubMed ID: 27020524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
    Oshida Y; Ikeda Y; Chaki S; Okuyama S
    Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
    Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.
    Takeda K; Terauchi T; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4756-61. PubMed ID: 22683343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
    Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Webb TR; Gu J; Xie YF; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3375-9. PubMed ID: 12951129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
    Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
    J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists.
    Nakazato A; Kumagai T; Okubo T; Tanaka H; Chaki S; Okuyama S; Tomisawa K
    Bioorg Med Chem; 2000 May; 8(5):1183-93. PubMed ID: 10882028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.